146 related articles for article (PubMed ID: 28445715)
21. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
Cerasa A; Salsone M; Morelli M; Pugliese P; Arabia G; Gioia CM; Novellino F; Quattrone A
Parkinsonism Relat Disord; 2013 Oct; 19(10):883-8. PubMed ID: 23769805
[TBL] [Abstract][Full Text] [Related]
22. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
[TBL] [Abstract][Full Text] [Related]
23. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Rogers JT; Devoto P; Björklund A; Carta M
Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
[TBL] [Abstract][Full Text] [Related]
24. Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease.
Wang Y; Zhang QJ; Liu J; Ali U; Gui ZH; Hui YP; Chen L; Wu ZH; Li Q
Brain Res; 2010 Jan; 1310():189-99. PubMed ID: 19896932
[TBL] [Abstract][Full Text] [Related]
25. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Yin LL; Geng XC; Zhu XZ
Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
[TBL] [Abstract][Full Text] [Related]
26. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
[TBL] [Abstract][Full Text] [Related]
27. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
28. Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
Lindenbach D; Conti MM; Ostock CY; Dupre KB; Bishop C
Neuroscience; 2015 Dec; 310():12-26. PubMed ID: 26363150
[TBL] [Abstract][Full Text] [Related]
29. Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Sgroi S; Capper-Loup C; Paganetti P; Kaelin-Lang A
Exp Neurol; 2016 Jun; 280():80-8. PubMed ID: 27072528
[TBL] [Abstract][Full Text] [Related]
30. In vivo effects of activation and blockade of 5-HT(2A/2C) receptors in the firing activity of pyramidal neurons of medial prefrontal cortex in a rodent model of Parkinson's disease.
Wang S; Zhang QJ; Liu J; Ali U; Wu ZH; Chen L; Gui ZH; Wang Y; Hui YP
Exp Neurol; 2009 Sep; 219(1):239-48. PubMed ID: 19500571
[TBL] [Abstract][Full Text] [Related]
31. Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.
Marin C; Aguilar E; Mengod G; Cortés R; Obeso JA
Eur J Neurosci; 2009 Sep; 30(5):823-32. PubMed ID: 19712101
[TBL] [Abstract][Full Text] [Related]
32. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
[TBL] [Abstract][Full Text] [Related]
33. Oscillatory pallidal local field potential activity inversely correlates with limb dyskinesias in Parkinson's disease.
Silberstein P; Oliviero A; Di Lazzaro V; Insola A; Mazzone P; Brown P
Exp Neurol; 2005 Aug; 194(2):523-9. PubMed ID: 16022875
[TBL] [Abstract][Full Text] [Related]
34. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
35. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
36. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
[TBL] [Abstract][Full Text] [Related]
37. Dopamine lesion-induced changes in subthalamic nucleus activity are not associated with alterations in firing rate or pattern in layer V neurons of the anterior cingulate cortex in anesthetized rats.
Parr-Brownlie LC; Poloskey SL; Flanagan KK; Eisenhofer G; Bergstrom DA; Walters JR
Eur J Neurosci; 2007 Oct; 26(7):1925-39. PubMed ID: 17897398
[TBL] [Abstract][Full Text] [Related]
38. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
[TBL] [Abstract][Full Text] [Related]
39. Axial levodopa-induced dyskinesias and neuronal activity in the dorsal striatum.
Alberico SL; Kim YC; Lence T; Narayanan NS
Neuroscience; 2017 Feb; 343():240-249. PubMed ID: 27956068
[TBL] [Abstract][Full Text] [Related]
40. Paradoxical facilitation after depotentiation protocol can precede dyskinesia onset in early Parkinson's disease.
Lago-Rodriguez A; Ponzo V; Jenkinson N; Benitez-Rivero S; Del-Olmo MF; Hu M; Koch G; Cheeran B
Exp Brain Res; 2016 Dec; 234(12):3659-3667. PubMed ID: 27566172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
